Literature DB >> 22351766

Molecular basis for failure of "atypical" C1 domain of Vav1 to bind diacylglycerol/phorbol ester.

Tamas Geczy1, Megan L Peach, Saïd El Kazzouli, Dina M Sigano, Ji-Hye Kang, Christopher J Valle, Julia Selezneva, Wonhee Woo, Noemi Kedei, Nancy E Lewin, Susan H Garfield, Langston Lim, Poonam Mannan, Victor E Marquez, Peter M Blumberg.   

Abstract

C1 domains, the recognition motif of the second messenger diacylglycerol and of the phorbol esters, are classified as typical (ligand-responsive) or atypical (not ligand-responsive). The C1 domain of Vav1, a guanine nucleotide exchange factor, plays a critical role in regulation of Vav activity through stabilization of the Dbl homology domain, which is responsible for exchange activity of Vav. Although the C1 domain of Vav1 is classified as atypical, it retains a binding pocket geometry homologous to that of the typical C1 domains of PKCs. This study clarifies the basis for its failure to bind ligands. Substituting Vav1-specific residues into the C1b domain of PKCδ, we identified five crucial residues (Glu(9), Glu(10), Thr(11), Thr(24), and Tyr(26)) along the rim of the binding cleft that weaken binding potency in a cumulative fashion. Reciprocally, replacing these incompatible residues in the Vav1 C1 domain with the corresponding residues from PKCδ C1b (δC1b) conferred high potency for phorbol ester binding. Computer modeling predicts that these unique residues in Vav1 increase the hydrophilicity of the rim of the binding pocket, impairing membrane association and thereby preventing formation of the ternary C1-ligand-membrane binding complex. The initial design of diacylglycerol-lactones to exploit these Vav1 unique residues showed enhanced selectivity for C1 domains incorporating these residues, suggesting a strategy for the development of ligands targeting Vav1.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22351766      PMCID: PMC3340006          DOI: 10.1074/jbc.M111.320010

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  65 in total

Review 1.  Ion pair transport across membranes.

Authors:  R Neubert
Journal:  Pharm Res       Date:  1989-09       Impact factor: 4.200

2.  The cysteine-rich domain of human proteins, neuronal chimaerin, protein kinase C and diacylglycerol kinase binds zinc. Evidence for the involvement of a zinc-dependent structure in phorbol ester binding.

Authors:  S Ahmed; R Kozma; J Lee; C Monfries; N Harden; L Lim
Journal:  Biochem J       Date:  1991-11-15       Impact factor: 3.857

3.  A new approach to analysis and display of local lipophilicity/hydrophilicity mapped on molecular surfaces.

Authors:  W Heiden; G Moeckel; J Brickmann
Journal:  J Comput Aided Mol Des       Date:  1993-10       Impact factor: 3.686

4.  Probing the determinants of diacylglycerol binding affinity in the C1B domain of protein kinase Cα.

Authors:  Mikaela D Stewart; Brittany Morgan; Francesca Massi; Tatyana I Igumenova
Journal:  J Mol Biol       Date:  2011-03-17       Impact factor: 5.469

5.  Structural mechanism for lipid activation of the Rac-specific GAP, beta2-chimaerin.

Authors:  Bertram Canagarajah; Federico Coluccio Leskow; Jonathan Yew Seng Ho; Harald Mischak; Layla F Saidi; Marcelo G Kazanietz; James H Hurley
Journal:  Cell       Date:  2004-10-29       Impact factor: 41.582

6.  Defective T-cell receptor signalling and positive selection of Vav-deficient CD4+ CD8+ thymocytes.

Authors:  K D Fischer; A Zmuldzinas; S Gardner; M Barbacid; A Bernstein; C Guidos
Journal:  Nature       Date:  1995-03-30       Impact factor: 49.962

7.  Mechanism of diacylglycerol-induced membrane targeting and activation of protein kinase Cdelta.

Authors:  Robert V Stahelin; Michelle A Digman; Martina Medkova; Bharath Ananthanarayanan; John D Rafter; Heather R Melowic; Wonhwa Cho
Journal:  J Biol Chem       Date:  2004-04-22       Impact factor: 5.157

8.  Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products.

Authors:  M G Kazanietz; X R Bustelo; M Barbacid; W Kolch; H Mischak; G Wong; G R Pettit; J D Bruns; P M Blumberg
Journal:  J Biol Chem       Date:  1994-04-15       Impact factor: 5.157

9.  Direct stimulation of Vav guanine nucleotide exchange activity for Ras by phorbol esters and diglycerides.

Authors:  E Gulbins; K M Coggeshall; G Baier; D Telford; C Langlet; G Baier-Bitterlich; N Bonnefoy-Berard; P Burn; A Wittinghofer; A Altman
Journal:  Mol Cell Biol       Date:  1994-07       Impact factor: 4.272

10.  vav, a novel human oncogene derived from a locus ubiquitously expressed in hematopoietic cells.

Authors:  S Katzav; D Martin-Zanca; M Barbacid
Journal:  EMBO J       Date:  1989-08       Impact factor: 11.598

View more
  11 in total

1.  Structural determinants of phorbol ester binding activity of the C1a and C1b domains of protein kinase C theta.

Authors:  Agnes Czikora; Satyabrata Pany; Youngki You; Amandeep S Saini; Nancy E Lewin; Gary A Mitchell; Adelle Abramovitz; Noemi Kedei; Peter M Blumberg; Joydip Das
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-01-06       Impact factor: 3.747

2.  Curcumin Inhibits Protein Kinase Cα Activity by Binding to Its C1 Domain.

Authors:  Satyabrata Pany; Youngki You; Joydip Das
Journal:  Biochemistry       Date:  2016-11-02       Impact factor: 3.162

3.  The C1 domain of Vav3, a novel potential therapeutic target.

Authors:  Jessica S Kelsey; Tamás Géczy; Christopher J Kaler; Peter M Blumberg
Journal:  Cell Signal       Date:  2017-09-18       Impact factor: 4.315

4.  Synthesis, biological, and biophysical studies of DAG-indololactones designed as selective activators of RasGRP.

Authors:  Lia C Garcia; Lucia Gandolfi Donadío; Ella Mann; Sofiya Kolusheva; Noemi Kedei; Nancy E Lewin; Colin S Hill; Jessica S Kelsey; Jing Yang; Timothy E Esch; Marina Santos; Megan L Peach; James A Kelley; Peter M Blumberg; Raz Jelinek; Victor E Marquez; Maria J Comin
Journal:  Bioorg Med Chem       Date:  2014-04-20       Impact factor: 3.641

5.  Charge density influences C1 domain ligand affinity and membrane interactions.

Authors:  Jessica S Kelsey; Tamas Geczy; Nancy E Lewin; Noemi Kedei; Colin S Hill; Julia S Selezneva; Christopher J Valle; Wonhee Woo; Inna Gorshkova; Peter M Blumberg
Journal:  Chembiochem       Date:  2014-04-28       Impact factor: 3.164

6.  Identification of the activator-binding residues in the second cysteine-rich regulatory domain of protein kinase Cθ (PKCθ).

Authors:  Ghazi M Rahman; Sreejesh Shanker; Nancy E Lewin; Noemi Kedei; Colin S Hill; B V Venkataram Prasad; Peter M Blumberg; Joydip Das
Journal:  Biochem J       Date:  2013-04-01       Impact factor: 3.857

7.  Structural Basis for the Failure of the C1 Domain of Ras Guanine Nucleotide Releasing Protein 2 (RasGRP2) to Bind Phorbol Ester with High Affinity.

Authors:  Agnes Czikora; Daniel J Lundberg; Adelle Abramovitz; Nancy E Lewin; Noemi Kedei; Megan L Peach; Xiaoling Zhou; Raymond C Merritt; Elizabeth A Craft; Derek C Braun; Peter M Blumberg
Journal:  J Biol Chem       Date:  2016-03-28       Impact factor: 5.157

8.  Bruton's Tyrosine Kinase (BTK) and Vav1 contribute to Dectin1-dependent phagocytosis of Candida albicans in macrophages.

Authors:  Karin Strijbis; Fikadu G Tafesse; Gregory D Fairn; Martin D Witte; Stephanie K Dougan; Nicki Watson; Eric Spooner; Alexandre Esteban; Valmik K Vyas; Gerald R Fink; Sergio Grinstein; Hidde L Ploegh
Journal:  PLoS Pathog       Date:  2013-06-27       Impact factor: 6.823

9.  Diacylglycerol lactones targeting the structural features that distinguish the atypical C1 domains of protein kinase C ζ and ι from typical C1 domains.

Authors:  Yongmei Pu; Ji-Hye Kang; Dina M Sigano; Megan L Peach; Nancy E Lewin; Victor E Marquez; Peter M Blumberg
Journal:  J Med Chem       Date:  2014-04-17       Impact factor: 7.446

10.  PKC activation by resveratrol derivatives with unsaturated aliphatic chain.

Authors:  Satyabrata Pany; Anjoy Majhi; Joydip Das
Journal:  PLoS One       Date:  2012-12-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.